Complement-Based Drug Development Summit leaderboard
  • Tuesday, October 6, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 42

Vir Biotechnology and Astellas Announce $1.71B Partnership, Accelerating Innovation in…

Mar 19, 2026
Another major milestone has reshaped the T‑cell engager landscape. Vir Biotechnology and Astellas Pharma have entered a new global strategic partnership valued at $1.71 billion to…
Read More...

FDA Approves First Oral IL-23 Blocker for Psoriasis

Mar 19, 2026
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), a novel oral therapy for the treatment of moderate-to-severe…
Read More...

Voro, Daiichi Sankyo Partner on Tumor-Activated ADCs

Mar 18, 2026
Voro Therapeutics has entered into a research collaboration with Daiichi Sankyo to develop next-generation antibody-drug conjugates (ADCs) using its proprietary PrimeBody platform. The…
Read More...

Terumo BCT, Taiwan Bio Partner on Treg Manufacturing

Mar 18, 2026
Terumo Blood and Cell Technologies (Terumo BCT) has entered into a strategic collaboration with Taiwan Bio Therapeutics Inc. to advance the manufacturing of regulatory T-cell (Treg)…
Read More...

R1 Therapeutics Launches With $77.5M to Advance Kidney Drug

Mar 18, 2026
R1 Therapeutics has officially launched as a new clinical-stage biopharmaceutical company, backed by an oversubscribed $77.5 million Series A financing and a strategic licensing…
Read More...

FDA Reviews ILUMYA for Psoriatic Arthritis Treatment

Mar 18, 2026
Sun Pharmaceutical Industries Limited has announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for…
Read More...

FDA Rejects Reproxalap NDA Over Efficacy Concerns

Mar 18, 2026
Aldeyra Therapeutics has received a setback in its efforts to bring a new treatment for dry eye disease to market, following a Complete Response Letter (CRL) issued by the U.S. Food and…
Read More...

How SmartLab Exchange USA Helped Uncountable Accelerate High‑Value R&D Partnerships

Mar 18, 2026
For fast‑growing digitalization leaders like Uncountable, accessing the right scientific and R&D decision makers is essential. Before joining the SmartLab Exchange USA, the company…
Read More...

Digital Transformation and AI-Powered Discovery in Modern Laboratories

Mar 18, 2026
Across materials science, chemistry, and pharmaceutical R&D, laboratories are moving beyond slow, sequential experimentation toward AI‑integrated discovery. One of the most…
Read More...

Roche Expands AI Infrastructure With Massive GPU Investment

Mar 17, 2026
Roche has announced a major expansion of its global artificial intelligence (AI) infrastructure, unveiling a large-scale “AI factory” powered by next-generation accelerated computing…
Read More...
Previous 1 … 40 41 42 43 44 … 956 Next
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
10th IPF Summit
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
17th World ADC San Diego
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Sanofi, Regeneron Expand Antibody Collaboration With $8B Deal
  • Abogen, Novartis Sign $7.2B RNA Therapeutics Deal
  • CAS, Novartis Partner on AI-Ready Reaction Data for Drug Discovery
  • SK pharmteco Invests $200M to Expand U.S. Drug Manufacturing
  • AstraZeneca Invests $2B in Summit Therapeutics for Cancer Research

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

FDA, Health Canada & Leading Biopharma Organizations…

Industry Leaders Convene in Boston as Registration Remains…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.